[Skip to Navigation]
Views 1,028
Citations 0
Observation
March 13, 2019

Occurrence of Extensive Cutaneous Human Papillomavirus Infection After Initiation of Tofacitinib Therapy

Author Affiliations
  • 1Department of Dermatology, Bichat Claude Bernard Hospital, AP-HP, Paris, France
  • 2INSERM UMR-1137, IAME, University of Paris Diderot, Sorbonne Paris Cité, Laboratoire de Virologie, Hôpital Bichat
  • 3Department of Gastroenterology, Beaujon Hospital, AP-HP, Paris France
  • 4Department of Pathology, Bichat Claude Bernard Hospital, AP-HP, Paris, France
  • 5INSERM UMR-1160, Institut Universitaire d’Hématologie, University of Paris Diderot, Sorbonne Paris Cité
JAMA Dermatol. 2019;155(5):629-631. doi:10.1001/jamadermatol.2018.5528

Tofacitinib is an oral inhibitor of Janus kinase (JAK) that selectively targets JAK1 and JAK3 and induces a modulation of the immune response.1 Tofacitinib has shown good results in patients with rheumatoid arthritis and inflammatory bowel disease and has a safety profile similar to that of tumor necrosis factor blockers; the most frequent adverse events are infections. Herein we report the first case to our knowledge of extensive cutaneous human papillomavirus (HPV) infection occurring shortly after initiation of tofacitinib therapy.

Add or change institution
×